JPMorgan Targets Weight Loss Drugs With $500M Fund
JPMorgan Private Capital has raised over $500 million for a life sciences fund targeting private biotech companies and the booming weight-loss drug space.
Read More from the Global Wellness News ™
- Enveda raises $55M to combine ancient remedies with AI for drug discovery
- Gen Z is abandoning alcohol